查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
重症肌無力治療市場，按藥物類別、按年齡層、按配銷通路、按國家和地區分類 - 2023-2030 年行業分析、市場規模、市場佔有率和預測
市場調查報告書
商品編碼
1388792

重症肌無力治療市場，按藥物類別、按年齡層、按配銷通路、按國家和地區分類 - 2023-2030 年行業分析、市場規模、市場佔有率和預測

Myasthenia Gravis Treatment Market, By Drug Class, By Age Group, By Distribution Channel, By Country, and By Region -Industry Analysis, Market Size, Market Share & Forecast from 2023-2030
出版日期: | 出版商: AnalystView Market Insights | 英文 303 Pages | 商品交期: 2-3個工作天內

價格

報告要點

2022年重症肌無力治療市場規模為201,243萬美元，2023年至2030年複合CAGR為9.4%。

重症肌無力（MG）是一種慢性、罕見、進行性神經肌肉疾病，會導致頭部、眼睛、四肢、脊椎和呼吸肌無力。這些自體免疫疾病中會產生針對乙醯膽鹼受體（AchR）的抗體，阻止從神經到肌肉的正常電訊號傳遞。此外，顏面神經麻痺、眼瞼下垂、複視和行走困難也是重症肌無力的症狀。這些疾病可透過多種測試來診斷，包括抗體血液檢查、磁振造影（MRI）、依酚銨測試、重複神經刺激測試和電腦斷層掃描（CT）。

重症肌無力治療市場-市場動態

全球重症肌無力盛行率的上升和人們對重症肌無力的認知的提高推動了市場的成長

全球重症肌無力發病率的上升，重症肌無力創新治療方法的採用以及早期診斷知識的增加是推動重症肌無力治療市場發展的主要驅動力。此外，製藥公司越來越關注疾病治療新藥的開發，重症肌無力治療市場也出現了顯著成長。此外，測試和開發各種藥物，包括免疫抑制劑和單株抗體，以了解其治療重症肌無力的功效。然而，與用於治療重症肌無力的藥物相關的副作用預計將很快抑制市場成長。此外，醫療保健專業人員和患者對重症肌無力的認知不斷提高，這在很大程度上促進了對有效治療的需求的增加。與此一致的是，隨著越來越多的人意識到重症肌無力的症狀和風險，人們更有可能尋求重症肌無力的治療和診斷。醫療保健專業人員對這種疾病及其可用治療方法的了解也越來越多，導致對有效治療的需求增加。

重症肌無力治療市場 - 關鍵見解

  • 根據研究分析師的分析，預計全球重症肌無力治療市場在預測期內（2023-2030年）每年將以 9.4%左右的CAGR成長
  • 由於醫療保健專業人員和患者對重症肌無力的認知不斷提高，重症肌無力治療行業預計將以顯著的速度成長
  • 根據藥物類別細分，預計單株抗體在2022年顯示最大的市場佔有率
  • 從配銷通路細分來看，醫院藥局是2022年的主導類型

政府提高重症肌無力意識和改善醫療基礎設施的措施推動市場成長。

重症肌無力治療市場-細分分析：

全球重症肌無力治療市場依據藥物類別、年齡層、配銷通路和地區進行細分。

根據藥物類別，市場分為五類：胸腺切除術、單株抗體、膽鹼酯酶抑制劑、快速免疫療法、慢性免疫調節劑等。由於治療重症肌無力的精度高且療效提高，單株抗體領域預計將佔據最高的市場佔有率。擴大使用單株抗體目的是減少終生接觸皮質類固醇並改善長期結果。

根據分銷管道，市場分為三類：藥局和零售藥局、醫院藥局和線上提供者。醫院藥房部門可能會在預測期內保持其主導地位。該細分市場歸因於對先進設備的高需求以及醫院環境中用於 MG 治療的大量患者庫。此外，此類設施提供廣泛的治療選擇，增加了接受治療和診斷的患者就診次數。對最先進的醫療基礎設施的投資不斷增加是其佔據巨大佔有率的主要因素。

重症肌無力治療市場 - 地理洞察

從地理上看，該市場分為北美、拉丁美洲、歐洲、亞太地區、中東和非洲地區。這些區域根據開展業務的國家進一步細分。北美在重症肌無力治療方面擁有最大的市場佔有率。自體免疫疾病評估的成長、提供創新藥物的重要公司的存在、重症肌無力的高發病率以及改善的醫療基礎設施的可及性都預計將推動重症肌無力治療產業的發展。此外，由於有關自體免疫疾病和可用治療方案的認知活動的增加、自體免疫疾病數量的增加以及對開發重症肌無力有效治療方案的投資增加，亞太地區的成長預計將顯著。此外，在新興經濟體中，醫療保健支出的激增預計將為市場擴張提供利潤豐厚的機會，推動重症肌無力治療市場的發展。

重症肌無力治療市場-競爭格局：

政府等一些組織為個人提供有關自體免疫疾病的諮詢。由於與傳統購買方式相比，消費者對網路購物的偏好增加，電子商務已成為全球大大小小的企業的重要工具。此外，一些透過健康應用程式來教育人們有關藥物使用和重症肌無力的動畫也促進了重症肌無力治療市場的成長。此外，主要市場參與者已採取策略聯盟、收購、產品核准、擴張和協議作為關鍵發展策略，以增強重症肌無力治療產業的產品組合。例如，2021年 3月，致力於改善全世界人民健康和福祉的全球醫療保健公司 Grifols 宣布收購 GigaGen Inc.，以推動產生多種免疫球蛋白的新方法。

最近的發展：

例如，2023年 4月，全球生技公司 CSL Behring 的 Hizentra 50mL/10gm 預充式注射器獲得 FDA 核准。 CSL Behring 提供各種尺寸的預充式注射器，以滿足原發性免疫缺陷和慢性發炎性脫髓鞘性多發性神經病變患者的特定需求。

目錄

第1章 重症肌無力治療市場概述

  • 研究範圍
  • 市場預估年份

第2章 執行摘要

  • 市場摘要
    • 依藥物類別分類的重症肌無力治療市場摘要
    • 按年齡層別分類的重症肌無力治療市場摘要
    • 依配銷通路的重症肌無力治療市場摘要
    • 依國家分類的重症肌無力治療市場摘要
    • 依地區分類的重症肌無力治療市場摘要
  • 競爭洞察

第3章 重症肌無力治療主要市場趨勢

  • 重症肌無力治療市場促進因素
    • 市場促進因素的影響分析
  • 重症肌無力治療市場限制
    • 市場限制影響分析
  • 重症肌無力治療市場機會
  • 重症肌無力治療市場未來趨勢

第4章 重症肌無力治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章 重症肌無力治療市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第6章 重症肌無力治療市場格局

  • 2022年重症肌無力治療市佔率分析
  • 細分資料：按主要製造商
    • 既有參與者分析
    • 新興參與者分析

第7章 重症肌無力治療市場 - 依藥物類別

  • 概述
    • 依藥物類別分類的細分市場佔有率分析
    • 胸腺切除術
    • 單株抗體
    • 膽鹼酯酶抑制劑
    • 快速免疫療法
    • 慢性免疫調節劑
    • 其他

第8章 重症肌無力治療市場 - 按年齡層

  • 概述
    • 按年齡層別分類的細分市場佔有率分析
    • 55歲以下
    • 55歲以上

第9章 重症肌無力治療市場 - 依配銷通路

  • 概述
    • 依配銷通路分類的細分市場佔有率分析
    • 藥局和零售藥局
    • 醫院藥房
    • 線上提供者

第10章 重症肌無力治療市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美重症肌無力治療主要製造商
    • 北美市場規模和預測（依國家）
    • 北美市場規模和預測（依藥物類別）
    • 北美市場規模和預測（依年齡層）
    • 北美市場規模和預測（依配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲重症肌無力治療主要製造商
    • 歐洲市場規模和預測（依國家）
    • 歐洲市場規模和預測（依藥物類別）
    • 歐洲市場規模和預測（依年齡層）
    • 歐洲市場規模和預測（依配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區（APAC）
    • 概述
    • 亞太地區重症肌無力治療主要製造商
    • 亞太地區市場規模與預測（依國家）
    • 亞太地區市場規模和預測（依藥物類別）
    • 亞太地區市場規模與預測（依年齡層）
    • 亞太地區市場規模和預測（依配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲重症肌無力治療主要製造商
    • 拉丁美洲市場規模與預測（依國家）
    • 拉丁美洲市場規模與預測（依藥物類別）
    • 拉丁美洲市場規模與預測（依年齡層）
    • 拉丁美洲市場規模和預測（依配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲重症肌無力治療主要製造商
    • 中東和非洲市場規模及預測（依國家）
    • 中東和非洲市場規模及預測（依藥物類別）
    • 中東和非洲市場規模及預測（依年齡層）
    • 中東和非洲市場規模及預測（依配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第11章 主要供應商分析 - 重症肌無力治療產業

  • 競爭儀表板
  • 公司簡介
    • F.Hoffmann-La Roche AG
    • Alexion Pharmaceutical Inc.
    • Zydus Lifesciences Limited
    • Grifols SA
    • Shire plc
    • Kedrion
    • Avadel Pharmaceuticals, Plc.
    • Octapharma AG
    • Novartis
    • Bausch Health Companies Inc.
    • Pfizer, Inc.
    • AbbVie Inc.
    • GlaxoSmithKline Plc.

第12章 360 度分析師視角

第13章 附錄

  • 研究方法論
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
Product Code: ANV1846

REPORT HIGHLIGHT

Myasthenia gravis treatment market size was valued at USD 2,012.43 Million in 2022, expanding at a CAGR of 9.4% from 2023 to 2030.

Myasthenia gravis (MG) is a type of chronic, rare, and progressive neuromuscular disorder that causes weakness of the head, eye, limb, spinal, and respiratory muscles. Antibodies against the acetylcholine receptor (AchR) that prevent proper electrical signal transmission from nerves to muscles are produced in these autoimmune disorders. Additionally, facial paralysis, drooping of eyelids, double vision, and difficulty in walking are symptoms of myasthenia gravis. These diseases are diagnosed by numerous tests including blood tests for antibodies, Magnetic Resonance Imaging (MRI), edrophonium test, repetitive nerve stimulation test, and Computed Tomography (CT).

Myasthenia Gravis Treatment Market- Market Dynamics

Rising prevalence and increasing awareness about myasthenia gravis worldwide driving the market growth

The rising global incidence of myasthenia gravis, the adoption of innovative treatments for myasthenia gravis, and increased knowledge about early diagnosis are the primary drivers driving the development of the myasthenia gravis treatment market. Moreover, the growing focus of pharmaceutical companies on the development of novel drugs for disease treatment is witnessing significant growth in the myasthenia gravis treatment market. Additionally, various medications, including immunosuppressants and monoclonal antibodies, are being tested and developed for their efficacy in treating myasthenia gravis. However, side effects associated with the drugs used for treating myasthenia gravis are expected to restrain the market growth shortly. Furthermore, rising awareness about myasthenia gravis among healthcare professionals and patients is majorly contributing to the increase in demand for effective treatments. In line with this, individuals are more likely to seek treatment and diagnosis for myasthenia gravis as more people become aware of its signs and risks. Healthcare professionals are also becoming more knowledgeable about the disease and its available treatments, leading to an increased demand for efficient treatments.

Myasthenia Gravis Treatment Market- Key Insights

  • As per the analysis shared by our research analyst, the global myasthenia gravis treatment market is estimated to grow annually at a CAGR of around 9.4% over the forecast period (2023-2030)
  • The myasthenia gravis treatment industry is projected to grow at a significant rate due to the rising awareness about myasthenia gravis among healthcare professionals and patients
  • Based on drug class segmentation, monoclonal antibodies was predicted to show maximum market share in the year 2022
  • Based on distribution channel segmentation, hospital pharmacies was the leading type in 2022

Government initiatives to increase consciousness regarding myasthenia gravis and improve healthcare infrastructure are fueling the market growth.

Myasthenia Gravis Treatment Market- Segmentation Analysis:

The global myasthenia gravis treatment market is segmented on the basis of drug class, age group, distribution channel, and region.

The market is divided into five categories based on drug class: thymectomy, monoclonal antibodies, cholinesterase inhibitors, rapid immunotherapies, chronic immunomodulators, and others. The monoclonal antibodies segment is expected to hold the highest market share due to the high precision in treating myasthenia gravis and improved efficacy. The rising use of monoclonal antibodies aims to reduce lifelong exposure to corticosteroids and improve long-term results.

The market is divided into three categories based on distribution channels: drugstore and retail pharmacies, hospital pharmacies, and online providers. The hospital pharmacies segment is likely to maintain its dominance over the forecast period. The segment is attributed to access to the high demand for advanced equipment and a large patient pool for MG treatment in hospital settings. Additionally, the availability of a broad range of treatment options in such facilities has increased patient visits for treatment and diagnosis. The rising investment in state-of-the-art healthcare infrastructures is the prime factor contributing to its large share.

Myasthenia Gravis Treatment Market- Geographical Insights

Geographically, this market is analyzed into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further segmented as per the nations bringing business. North America has the biggest market share for myasthenia gravis therapy. The growth in autoimmune disease evaluation, the existence of significant companies providing innovative medicines, the high incidence of myasthenia gravis, and the accessibility of improved healthcare infrastructure are all expected to drive the myasthenia gravis treatment industry. Moreover, Asia-Pacific is accounted to witness notable growth due to the increase in awareness campaigns regarding autoimmune diseases & available treatment options, rising number of autoimmune diseases, and rising investments for the development of effective treatment options for myasthenia gravis. In addition, in emerging economies upsurge in healthcare expenditure is anticipated to provide lucrative opportunities for market expansion, driving the myasthenia gravis treatment market.

Myasthenia Gravis Treatment Market- Competitive Landscape:

Several organizations such as the government are counseling individuals regarding autoimmune diseases. E-commerce has become a vital tool for large and small businesses across the globe, due to the increase in the preference of consumers for online shopping as compared to traditional purchasing methods. Additionally, several animations through health apps to educate people regarding the usage of medications and myasthenia gravis have contributed toward the myasthenia gravis treatment market growth. Moreover, major market players have adopted strategic alliance, acquisition, product approval, expansion, and agreement as key developmental strategies to enhance the product portfolio of the myasthenia gravis treatment industry. For instance, in March 2021, Grifols a global healthcare company to improve the health and well-being of people worldwide announced to acquire GigaGen Inc. to boost a novel method to generate a broad range of immunoglobulins.

Recent Developments:

For instance, in April 2023, CSL Behring, a global biotechnology company, has received FDA approval for a 50mL/10gm prefilled syringe for Hizentra. CSL Behring offers a comprehensive variety of prefilled syringe sizes to satisfy the specific needs of persons suffering from Primary Immunodeficiency as well as Chronic Inflammatory Demyelinating Polyneuropathy.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET KEY PLAYERS

  • F.Hoffmann-La Roche AG
  • Alexion Pharmaceutical Inc.
  • Zydus Lifesciences Limited
  • Grifols SA
  • Shire plc
  • Kedrion
  • Avadel Pharmaceuticals, Plc.
  • Octapharma AG
  • Novartis
  • Bausch Health Companies Inc.
  • Pfizer, Inc.
  • AbbVie Inc.
  • GlaxoSmithKline Plc.

GLOBALMYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS

  • Thymectomy
  • Monoclonal Antibodies
  • Cholinesterase Inhibitors
  • Rapid Immunotherapies
  • Chronic Immunomodulators
  • Others

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP

  • Below 55 years
  • Above 55 years

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • Drug store and retail pharmacies
  • Hospital pharmacies
  • Online providers

GLOBAL MYASTHENIA GRAVIS TREATMENT MARKET, BY REGION

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • Spain
    • United Kingdom
    • Russia
    • Netherlands
    • Sweden
    • Poland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Colombia
    • Rest of LATAM
  • The Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Turkey
    • Algeria
    • Egypt
    • Rest of MEA

Table of Contents

1. Myasthenia Gravis Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Myasthenia Gravis Treatment Market Snippet by Drug Class
    • 2.1.2. Myasthenia Gravis Treatment Market Snippet by Age Group
    • 2.1.3. Myasthenia Gravis Treatment Market Snippet by Distribution Channel
    • 2.1.4. Myasthenia Gravis Treatment Market Snippet by Country
    • 2.1.5. Myasthenia Gravis Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Myasthenia Gravis Treatment Key Market Trends

  • 3.1. Myasthenia Gravis Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Myasthenia Gravis Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Myasthenia Gravis Treatment Market Opportunities
  • 3.4. Myasthenia Gravis Treatment Market Future Trends

4. Myasthenia Gravis Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Myasthenia Gravis Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Myasthenia Gravis Treatment Market Landscape

  • 6.1. Myasthenia Gravis Treatment Market Share Analysis, 2022
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Myasthenia Gravis Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2022&2030 (%)
    • 7.1.2. Thymectomy
    • 7.1.3. Monoclonal Antibodies
    • 7.1.4. Cholinesterase Inhibitors
    • 7.1.5. Rapid Immunotherapies
    • 7.1.6. Chronic Immunomodulators
    • 7.1.7. Others

8. Myasthenia Gravis Treatment Market - By Age Group

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Age Group, 2022&2030 (%)
    • 8.1.2. Below 55 years
    • 8.1.3. Above 55 years

9. Myasthenia Gravis Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2022&2030 (%)
    • 9.1.2. Drug store and retail pharmacies
    • 9.1.3. Hospital pharmacies
    • 9.1.4. Online providers

10. Myasthenia Gravis Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2022&2030 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Myasthenia Gravis Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Myasthenia Gravis Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Myasthenia Gravis Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Myasthenia Gravis Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Myasthenia Gravis Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2018 - 2030 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2018 - 2030, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Drug Class, 2018 - 2030 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Age Group, 2018 - 2030 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2018 - 2030 (US$ Million)

11. Key Vendor Analysis- Myasthenia Gravis Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. F.Hoffmann-La Roche AG
    • 11.2.2. Alexion Pharmaceutical Inc.
    • 11.2.3. Zydus Lifesciences Limited
    • 11.2.4. Grifols SA
    • 11.2.5. Shire plc
    • 11.2.6. Kedrion
    • 11.2.7. Avadel Pharmaceuticals, Plc.
    • 11.2.8. Octapharma AG
    • 11.2.9. Novartis
    • 11.2.10. Bausch Health Companies Inc.
    • 11.2.11. Pfizer, Inc.
    • 11.2.12. AbbVie Inc.
    • 11.2.13. GlaxoSmithKline Plc.

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE Myasthenia Gravis Treatment Market: Drug Class Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Drug Class
  • TABLE Global Myasthenia Gravis Treatment Market, by Drug Class2018-2030 (USD Million)
  • TABLE Myasthenia Gravis Treatment Market: Age GroupSnapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Age Group
  • TABLE Global Myasthenia Gravis Treatment Market, by Age Group2018-2030 (USD Million)
  • TABLE Myasthenia Gravis Treatment Market: Distribution Channel Snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Distribution Channel
  • TABLE Global Myasthenia Gravis Treatment Market, by Distribution Channel 2018-2030 (USD Million)
  • TABLE Myasthenia Gravis Treatment Market: Regional snapshot (2022)
  • TABLE Segment Dashboard; Definition and Scope, by Region
  • TABLE Global Myasthenia Gravis Treatment Market, by Region 2018-2030 (USD Million)
  • TABLE North America Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE North America Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE North America Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE North America Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Europe Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Europe Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Europe Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE Europe Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Asia Pacific Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Asia Pacific Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Asia Pacific Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE Asia Pacific Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Latin America Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Latin America Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Latin America Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE Latin America Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Myasthenia Gravis Treatment Market, by Country, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Myasthenia Gravis Treatment Market, by Drug Class, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Myasthenia Gravis Treatment Market, by Age Group, 2018-2030 (USD Million)
  • TABLE Middle East and Africa Myasthenia Gravis Treatment Market, by Distribution Channel, 2018-2030 (USD Million)

List of Figures

  • FIGURE Myasthenia Gravis Treatment Market Segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2022
  • FIGURE Drug Class segment market share analysis, 2022&2030
  • FIGURE Drug Class segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Age Group segment market share analysis, 2022&2030
  • FIGURE Age Group segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Distribution Channel segment market share analysis, 2022&2030
  • FIGURE Distribution Channel segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Regional segment market share analysis, 2022&2030
  • FIGURE Regional segment market size forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE North America Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE Europe Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE Asia Pacific Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE Latin America Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE Middle East and Africa Myasthenia Gravis Treatment Market share and leading players, 2022
  • FIGURE North America market share analysis by country, 2022
  • FIGURE U.S. Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Canada Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Europe Myasthenia Gravis Treatment Market share analysis by country, 2022
  • FIGURE Germany Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Spain Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Italy Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE France Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE UK Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Russia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Netherlands Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Sweden Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Poland Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of the Europe Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Asia Pacific Myasthenia Gravis Treatment Market share analysis by country, 2022
  • FIGURE India Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE China Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Japan Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE South Korea Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Australia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Thailand Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Indonesia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Phillipines Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of APAC Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Latin America Myasthenia Gravis Treatment Market share analysis by country, 2022
  • FIGURE Brazil Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Mexico Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Argentina Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Colombia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of LATAM Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Middle East and Africa Myasthenia Gravis Treatment Market share analysis by country, 2022
  • FIGURE Saudi Arabia Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE United Arab Emirates Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Israel Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Turkey Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Algeria Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Egypt Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)
  • FIGURE Rest of MEA Myasthenia Gravis Treatment Market size, forecast and trend analysis, 2018 to 2030 (USD Million)